Kyverna Therapeutics, Inc. (KYTX), Monday announced the appointment of Greg Martini as Chief Financial Officer, effective May 18.
The late-stage clinical biopharmaceutical company focused on autoimmune diseases said Martini will succeed Marc Grasso.
Martini has been with Ironwood Pharmaceuticals. Kyverna will grant Martini an option to purchase 325,000 shares of its common stock Option.
The Company said it is in the process of advancing miv-cel or KYV-101 toward a potential first approval in stiff person syndrome and prepares for its transition to a commercial-stage organization.
Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation, designed for potency and tolerability.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.